Literature DB >> 16237540

[Pharmacological potential of phytoestrogens in the treatment of prostate cancer].

P Thelen1, F Seseke, R-H Ringert, W Wuttke, D Seidlová-Wuttke.   

Abstract

INTRODUCTION: Phytoestrogenes are plant-derived compounds that have been shown to exert an antiproliferative potential on prostate cancer cells, although the exact mechanisms are still unclear. In prostate cancer cells proliferation is regulated by modulation of the IGF-1 receptor (IGF-R-1) by the androgen receptor (AR) and its co-activator prostate derived Ets factor (PDEF). Phytooestrogenes interact with these mechanisms as demonstrated exemplarily in the presented study with the isoflavone tectorigenin derived from Belamcanda chinensis.
MATERIAL AND METHODS: Cultured androgen-sensitive LNCaP prostate cancer cells were treated with tectorigenin of 100 microM for 24 hours. The mRNA-expression of AR, PSA, PDEF, hTERT, TIMP-3 and IGF-R-1 were quantified by real-time RT-PCR. Furthermore, the expression or activity of PSA, telomerase and IGF-R-1 was measured on the protein level. In addition, we investigated in nude mice the influence of a diet of extracts of Belamcanda chinensis on the growth of subcutaneously injected LNCaP cells versus a control group of animals fed with a soy-free diet.
RESULTS: In cultured LNCaP cells treatment with tectorigenin resulted in a significant down-regulation of the gene expression of AR, PDEF, PSA, IGF-R-1 and hTERT. On the protein level PSA secretion and the activity of telomerase and IGF-R-1 expression was also decreased. The gene expression of TIMP-3 was distinctly up-regulated by tectorigenin. Nude mice fed with Belamcanda chinensis extract showed a significantly decreased incidence and tumor growth compared to controls.
CONCLUSIONS: Tectorigenin shows an inhibition of the IGF-1-R modulated cell proliferation of PCa-Cells, due to modulation of the activity the co-activator PDEF independently from the AR. Furthermore, tectorigenin has pro-apoptotic effects and decreases tissue invasion by up-regulation of TIMP-3. Therefore, phytooestrogenes are an interesting option in the therapy of prostate especially advanced prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16237540     DOI: 10.1007/s00120-005-0932-3

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  18 in total

1.  Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway.

Authors:  Mark Bond; Gillian Murphy; Martin R Bennett; Andrew C Newby; Andrew H Baker
Journal:  J Biol Chem       Date:  2002-02-04       Impact factor: 5.157

2.  Signaling through estrogen receptors modulates telomerase activity in human prostate cancer.

Authors:  Simona Nanni; Michela Narducci; Linda Della Pietra; Fabiola Moretti; Annalisa Grasselli; Piero De Carli; Ada Sacchi; Alfredo Pontecorvi; Antonella Farsetti
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

3.  Tectorigenin, an isoflavone of Pueraria thunbergiana Benth., induces differentiation and apoptosis in human promyelocytic leukemia HL-60 cells.

Authors:  K T Lee; I C Sohn; Y K Kim; J H Choi; J W Choi; H J Park; Y Itoh; K Miyamoto
Journal:  Biol Pharm Bull       Date:  2001-10       Impact factor: 2.233

4.  Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.

Authors:  Giuseppe Pandini; Rossana Mineo; Francesco Frasca; Charles T Roberts; Marco Marcelli; Riccardo Vigneri; Antonino Belfiore
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

5.  Anti-angiogenic and anti-tumor activities of isoflavonoids from the rhizomes of Belamcanda chinensis.

Authors:  Sang Hoon Jung; Yeon Sil Lee; Sanghyun Lee; Soon Sung Lim; Yeong Shik Kim; Kazuo Ohuchi; Kuk Hyun Shin
Journal:  Planta Med       Date:  2003-07       Impact factor: 3.352

Review 6.  Phytoestrogens: recent developments.

Authors:  Paul Cos; Tess De Bruyne; Sandra Apers; Dirk Vanden Berghe; Luc Pieters; Arnold J Vlietinck
Journal:  Planta Med       Date:  2003-07       Impact factor: 3.352

7.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

8.  Blockade of the type I IGF receptor expression in human prostate cancer cells inhibits proliferation and invasion, up-regulates IGF binding protein-3, and suppresses MMP-2 expression.

Authors:  Michal Grzmil; Bernhard Hemmerlein; Paul Thelen; Stefan Schweyer; Peter Burfeind
Journal:  J Pathol       Date:  2004-01       Impact factor: 7.996

Review 9.  Role of TIMPs (tissue inhibitors of metalloproteinases) in pericellular proteolysis: the specificity is in the detail.

Authors:  Gillian Murphy; Vera Knäuper; Meng-Huee Lee; Augustin Amour; Joanna R Worley; Mike Hutton; Susan Atkinson; Magdalene Rapti; Richard Williamson
Journal:  Biochem Soc Symp       Date:  2003

10.  Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells.

Authors:  Shen Gao; Guo-Zhen Liu; Zhengxin Wang
Journal:  Prostate       Date:  2004-05-01       Impact factor: 4.104

View more
  2 in total

1.  Association of urinary phytoestrogen concentrations with serum concentrations of prostate-specific antigen in the National Health and Nutrition Examination Survey.

Authors:  Esther Walser-Domjan; Aline Richard; Monika Eichholzer; Elizabeth A Platz; Jakob Linseisen; Sabine Rohrmann
Journal:  Nutr Cancer       Date:  2013       Impact factor: 2.900

2.  Pro-apoptotic effects of tectorigenin on human hepatocellular carcinoma HepG2 cells.

Authors:  Chun-Ping Jiang; Hui Ding; Da-Hua Shi; Yu-Rong Wang; Er-Guang Li; Jun-Hua Wu
Journal:  World J Gastroenterol       Date:  2012-04-21       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.